PMID- 15901287
OWN - NLM
STAT- MEDLINE
DCOM- 20050927
LR  - 20161124
IS  - 0742-2822 (Print)
IS  - 0742-2822 (Linking)
VI  - 22
IP  - 5
DP  - 2005 May
TI  - Correlation between right ventricular indices and clinical improvement in 
      epoprostenol treated pulmonary hypertension patients.
PG  - 374-9
AB  - The aim of this study was to evaluate which parameter of right ventricular (RV) 
      echocardiographic best mirrors the clinical status of patients with pulmonary 
      arterial hypertension. Patients with pulmonary arterial hypertension on 
      epoprostenol therapy were identified via hospital registry. Twenty patients, (16 
      females, 4 males) were included in the study, 9 with primary pulmonary 
      hypertension and 11 with other diseases. Echocardiograms before therapy and at 
      22.7 (+/-9.3) months into therapy were compared. The right ventricular myocardial 
      performance index (RVMPI) was measured as the sum of the isometric contraction 
      time and the isometric relaxation time divided by right ventricular ejection 
      time. Other measures included peak tricuspid regurgitation jet velocity (TRV), 
      pulmonary artery systolic pressure (PASP), pulmonary valve velocity time integral 
      (PVVTI), PASP/PVVTI (as an index of total pulmonary resistance) and symptoms by 
      New York Heart Association (NYHA) functional class. Echo parameters of right 
      ventricular function were analyzed in patients, before and during therapy. There 
      was significant improvement of NYHA class in patients following epoprostenol 
      therapy (P < 0.0001). Peak tricuspid regurgitant jet velocity (pre 4.2 +/- 0.6 
      m/sec, post 3.8 +/- 0.7 m/sec, P = 0.02) and PASP/PVVTI (pre 6.7 +/- 3.3 mmHg/m 
      per second, post 4.8 +/- 2.2 mmHg/m per second, P < 0.0001) were significantly 
      improved during treatment. RVMPI did not improve (pre 0.6 +/- 0.3, post 0.6 +/- 
      0.3, P = 0.54). Changes in NYHA class did not correlate with changes in RVMPI (P 
      = 0.33) or changes in PASP/PVVTI (P = 0.58). Despite significant improvements in 
      TRV, PASP/PVVTI, and NYHA class, there was no significant change in RVMPI on 
      epoprostenol therapy. Changes in right ventricular indices were not correlated 
      with changes in NYHA class.
FAU - Nath, Jayant
AU  - Nath J
AD  - University of Kansas Medical Center, Kansas City, Kansas, USA. jayant@pol.net
FAU - Demarco, Teresa
AU  - Demarco T
FAU - Hourigan, Lisa
AU  - Hourigan L
FAU - Heidenreich, Paul A
AU  - Heidenreich PA
FAU - Foster, Elyse
AU  - Foster E
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Echocardiography
JT  - Echocardiography (Mount Kisco, N.Y.)
JID - 8511187
RN  - 0 (Antihypertensive Agents)
RN  - DCR9Z582X0 (Epoprostenol)
SB  - IM
MH  - Antihypertensive Agents/*therapeutic use
MH  - Blood Flow Velocity/drug effects/physiology
MH  - Echocardiography, Doppler, Color
MH  - Epoprostenol/*therapeutic use
MH  - Female
MH  - Heart Ventricles/*diagnostic imaging/drug effects/physiopathology
MH  - Humans
MH  - Hypertension, Pulmonary/diagnostic imaging/*drug therapy/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Myocardial Contraction/drug effects/physiology
MH  - Observer Variation
MH  - Prognosis
MH  - Pulmonary Valve/diagnostic imaging/physiopathology
MH  - Pulmonary Wedge Pressure/drug effects/physiology
MH  - Reproducibility of Results
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Treatment Outcome
MH  - Ventricular Function, Right/drug effects/*physiology
EDAT- 2005/05/20 09:00
MHDA- 2005/09/28 09:00
CRDT- 2005/05/20 09:00
PHST- 2005/05/20 09:00 [pubmed]
PHST- 2005/09/28 09:00 [medline]
PHST- 2005/05/20 09:00 [entrez]
AID - ECHO04022 [pii]
AID - 10.1111/j.1540-8175.2005.04022.x [doi]
PST - ppublish
SO  - Echocardiography. 2005 May;22(5):374-9. doi: 10.1111/j.1540-8175.2005.04022.x.